Chemokine-enhanced DNA vaccination in cancer immunotherapy

We have demonstrated that priming of intratumoral and intradermal vaccination sites with chemokines enhances cytotoxic immune response against established neoplasms. Additional insights into the molecular mechanisms that underlie these findings and the optimization of such an approach may lead to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Igoucheva, Olga, Jonas, Rebecca, Alexeev, Vitali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827092/
https://www.ncbi.nlm.nih.gov/pubmed/24251079
http://dx.doi.org/10.4161/onci.26092
_version_ 1782291003716141056
author Igoucheva, Olga
Jonas, Rebecca
Alexeev, Vitali
author_facet Igoucheva, Olga
Jonas, Rebecca
Alexeev, Vitali
author_sort Igoucheva, Olga
collection PubMed
description We have demonstrated that priming of intratumoral and intradermal vaccination sites with chemokines enhances cytotoxic immune response against established neoplasms. Additional insights into the molecular mechanisms that underlie these findings and the optimization of such an approach may lead to the development of cost-effective and generic immunotherapeutic regimens against cancer.
format Online
Article
Text
id pubmed-3827092
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-38270922013-11-18 Chemokine-enhanced DNA vaccination in cancer immunotherapy Igoucheva, Olga Jonas, Rebecca Alexeev, Vitali Oncoimmunology Author's View We have demonstrated that priming of intratumoral and intradermal vaccination sites with chemokines enhances cytotoxic immune response against established neoplasms. Additional insights into the molecular mechanisms that underlie these findings and the optimization of such an approach may lead to the development of cost-effective and generic immunotherapeutic regimens against cancer. Landes Bioscience 2013-10-01 2013-09-12 /pmc/articles/PMC3827092/ /pubmed/24251079 http://dx.doi.org/10.4161/onci.26092 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Igoucheva, Olga
Jonas, Rebecca
Alexeev, Vitali
Chemokine-enhanced DNA vaccination in cancer immunotherapy
title Chemokine-enhanced DNA vaccination in cancer immunotherapy
title_full Chemokine-enhanced DNA vaccination in cancer immunotherapy
title_fullStr Chemokine-enhanced DNA vaccination in cancer immunotherapy
title_full_unstemmed Chemokine-enhanced DNA vaccination in cancer immunotherapy
title_short Chemokine-enhanced DNA vaccination in cancer immunotherapy
title_sort chemokine-enhanced dna vaccination in cancer immunotherapy
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827092/
https://www.ncbi.nlm.nih.gov/pubmed/24251079
http://dx.doi.org/10.4161/onci.26092
work_keys_str_mv AT igouchevaolga chemokineenhanceddnavaccinationincancerimmunotherapy
AT jonasrebecca chemokineenhanceddnavaccinationincancerimmunotherapy
AT alexeevvitali chemokineenhanceddnavaccinationincancerimmunotherapy

Ejemplares similares